Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.33
A's Cash to Debt is ranked lower than
61% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. A: 1.33 )
Ranked among companies with meaningful Cash to Debt only.
A' s 10-Year Cash to Debt Range
Min: 0.63  Med: 1.39 Max: No Debt
Current: 1.33
Equity to Asset 0.56
A's Equity to Asset is ranked lower than
57% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. A: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
A' s 10-Year Equity to Asset Range
Min: 0.31  Med: 0.50 Max: 0.71
Current: 0.56
0.31
0.71
Interest Coverage 7.35
A's Interest Coverage is ranked lower than
82% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. A: 7.35 )
Ranked among companies with meaningful Interest Coverage only.
A' s 10-Year Interest Coverage Range
Min: 0.53  Med: 8.45 Max: 9999.99
Current: 7.35
0.53
9999.99
F-Score: 6
Z-Score: 4.68
M-Score: -2.75
WACC vs ROIC
9.24%
9.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.24
A's Operating margin (%) is ranked higher than
79% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. A: 11.24 )
Ranked among companies with meaningful Operating margin (%) only.
A' s 10-Year Operating margin (%) Range
Min: -26.74  Med: 9.33 Max: 16.32
Current: 11.24
-26.74
16.32
Net-margin (%) 5.85
A's Net-margin (%) is ranked higher than
72% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. A: 5.85 )
Ranked among companies with meaningful Net-margin (%) only.
A' s 10-Year Net-margin (%) Range
Min: -46.06  Med: 8.09 Max: 66.5
Current: 5.85
-46.06
66.5
ROE (%) 6.51
A's ROE (%) is ranked higher than
63% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. A: 6.51 )
Ranked among companies with meaningful ROE (%) only.
A' s 10-Year ROE (%) Range
Min: -55.24  Med: 14.91 Max: 85.57
Current: 6.51
-55.24
85.57
ROA (%) 3.45
A's ROA (%) is ranked higher than
67% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.05 vs. A: 3.45 )
Ranked among companies with meaningful ROA (%) only.
A' s 10-Year ROA (%) Range
Min: -28.39  Med: 7.36 Max: 46.84
Current: 3.45
-28.39
46.84
ROC (Joel Greenblatt) (%) 35.04
A's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. A: 35.04 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
A' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -54.39  Med: 33.35 Max: 84.13
Current: 35.04
-54.39
84.13
Revenue Growth (3Y)(%) 3.50
A's Revenue Growth (3Y)(%) is ranked lower than
58% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. A: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
A' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22.8  Med: 4.80 Max: 18.4
Current: 3.5
-22.8
18.4
EBITDA Growth (3Y)(%) -4.30
A's EBITDA Growth (3Y)(%) is ranked lower than
59% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. A: -4.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
A' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27.7  Med: 9.70 Max: 76.8
Current: -4.3
-27.7
76.8
EPS Growth (3Y)(%) -19.40
A's EPS Growth (3Y)(%) is ranked lower than
70% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. A: -19.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
A' s 10-Year EPS Growth (3Y)(%) Range
Min: -19.4  Med: 11.20 Max: 135.6
Current: -19.4
-19.4
135.6
» A's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

A Guru Trades in Q3 2014

John Burbank 35,000 sh (New)
Jim Simons 187,500 sh (New)
Joel Greenblatt 372,199 sh (New)
PRIMECAP Management 2,813,589 sh (+2967.69%)
Paul Tudor Jones 209,138 sh (+62.65%)
First Eagle Investment 1,129,300 sh (+35.86%)
Signature Select Canadian Fund 257,600 sh (+34.45%)
John Keeley 48,840 sh (+4.72%)
David Dreman 2,411 sh (+3.39%)
Ron Baron 26,000 sh (unchged)
Vanguard Health Care Fund 5,624,200 sh (unchged)
Chris Davis 2,980,262 sh (-0.39%)
» More
Q4 2014

A Guru Trades in Q4 2014

Jeremy Grantham 110,000 sh (New)
Jim Simons 1,315,200 sh (+601.44%)
PRIMECAP Management 5,666,300 sh (+101.39%)
John Keeley 70,660 sh (+44.68%)
Ron Baron 33,900 sh (+30.38%)
Vanguard Health Care Fund 5,624,200 sh (unchged)
John Burbank Sold Out
David Dreman Sold Out
First Eagle Investment Sold Out
Chris Davis 2,969,653 sh (-0.36%)
Paul Tudor Jones 154,856 sh (-25.96%)
Joel Greenblatt 5,790 sh (-98.44%)
» More
Q1 2015

A Guru Trades in Q1 2015

Mario Gabelli 132,600 sh (New)
John Keeley 155,230 sh (+119.69%)
PRIMECAP Management 5,679,310 sh (+0.23%)
Vanguard Health Care Fund 5,624,200 sh (unchged)
Ron Baron 33,900 sh (unchged)
Signature Select Canadian Fund Sold Out
Joel Greenblatt Sold Out
Chris Davis 2,933,345 sh (-1.22%)
Jeremy Grantham 106,000 sh (-3.64%)
Jim Simons 1,012,600 sh (-23.01%)
Paul Tudor Jones 16,093 sh (-89.61%)
» More
Q2 2015

A Guru Trades in Q2 2015

Joel Greenblatt 225,893 sh (New)
Paul Tudor Jones 112,904 sh (+601.57%)
Mario Gabelli 166,700 sh (+25.72%)
Vanguard Health Care Fund 6,680,210 sh (+18.78%)
John Keeley 168,130 sh (+8.31%)
PRIMECAP Management 5,725,575 sh (+0.81%)
Jeremy Grantham 105,300 sh (-0.66%)
Ron Baron 28,900 sh (-14.75%)
Jim Simons 801,500 sh (-20.85%)
Chris Davis 71,209 sh (-97.57%)
» More
» Details

Insider Trades

Latest Guru Trades with A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 38.16
A's P/E(ttm) is ranked lower than
62% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.10 vs. A: 38.16 )
Ranked among companies with meaningful P/E(ttm) only.
A' s 10-Year P/E(ttm) Range
Min: 2.74  Med: 15.02 Max: 48.25
Current: 38.16
2.74
48.25
Forward P/E 18.55
A's Forward P/E is ranked higher than
57% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.12 vs. A: 18.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 34.20
A's PE(NRI) is ranked lower than
57% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.30 vs. A: 34.20 )
Ranked among companies with meaningful PE(NRI) only.
A' s 10-Year PE(NRI) Range
Min: 5.2  Med: 15.17 Max: 64.99
Current: 34.2
5.2
64.99
P/B 2.92
A's P/B is ranked higher than
55% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. A: 2.92 )
Ranked among companies with meaningful P/B only.
A' s 10-Year P/B Range
Min: 1.21  Med: 2.49 Max: 3.49
Current: 2.92
1.21
3.49
P/S 1.77
A's P/S is ranked higher than
62% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. A: 1.77 )
Ranked among companies with meaningful P/S only.
A' s 10-Year P/S Range
Min: 0.59  Med: 1.83 Max: 3.9
Current: 1.77
0.59
3.9
PFCF 63.01
A's PFCF is ranked lower than
73% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.28 vs. A: 63.01 )
Ranked among companies with meaningful PFCF only.
A' s 10-Year PFCF Range
Min: 5.38  Med: 14.04 Max: 75.09
Current: 63.01
5.38
75.09
POCF 34.78
A's POCF is ranked lower than
67% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. A: 34.78 )
Ranked among companies with meaningful POCF only.
A' s 10-Year POCF Range
Min: 4.31  Med: 11.77 Max: 41.48
Current: 34.78
4.31
41.48
EV-to-EBIT 20.61
A's EV-to-EBIT is ranked higher than
53% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.60 vs. A: 20.61 )
Ranked among companies with meaningful EV-to-EBIT only.
A' s 10-Year EV-to-EBIT Range
Min: -143.5  Med: 17.30 Max: 305.7
Current: 20.61
-143.5
305.7
PEG 1.22
A's PEG is ranked higher than
83% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.25 vs. A: 1.22 )
Ranked among companies with meaningful PEG only.
A' s 10-Year PEG Range
Min: 0.08  Med: 0.67 Max: 8.22
Current: 1.22
0.08
8.22
Shiller P/E 17.33
A's Shiller P/E is ranked higher than
89% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.03 vs. A: 17.33 )
Ranked among companies with meaningful Shiller P/E only.
A' s 10-Year Shiller P/E Range
Min: 6.37  Med: 17.64 Max: 87.11
Current: 17.33
6.37
87.11
Current Ratio 3.89
A's Current Ratio is ranked higher than
65% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. A: 3.89 )
Ranked among companies with meaningful Current Ratio only.
A' s 10-Year Current Ratio Range
Min: 1.61  Med: 2.51 Max: 3.94
Current: 3.89
1.61
3.94
Quick Ratio 3.29
A's Quick Ratio is ranked higher than
64% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. A: 3.29 )
Ranked among companies with meaningful Quick Ratio only.
A' s 10-Year Quick Ratio Range
Min: 1.04  Med: 1.98 Max: 3.33
Current: 3.29
1.04
3.33
Days Inventory 116.20
A's Days Inventory is ranked lower than
65% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. A: 116.20 )
Ranked among companies with meaningful Days Inventory only.
A' s 10-Year Days Inventory Range
Min: 91.25  Med: 113.45 Max: 151.03
Current: 116.2
91.25
151.03
Days Sales Outstanding 37.81
A's Days Sales Outstanding is ranked higher than
83% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. A: 37.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
A' s 10-Year Days Sales Outstanding Range
Min: 42.47  Med: 51.40 Max: 88.72
Current: 37.81
42.47
88.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.18
A's Dividend Yield is ranked lower than
63% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. A: 1.18 )
Ranked among companies with meaningful Dividend Yield only.
A' s 10-Year Dividend Yield Range
Min: 0.31  Med: 1.22 Max: 1.42
Current: 1.18
0.31
1.42
Dividend Payout 0.29
A's Dividend Payout is ranked higher than
61% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.33 vs. A: 0.29 )
Ranked among companies with meaningful Dividend Payout only.
A' s 10-Year Dividend Payout Range
Min: 0.09  Med: 0.25 Max: 1.94
Current: 0.29
0.09
1.94
Yield on cost (5-Year) 1.18
A's Yield on cost (5-Year) is ranked lower than
64% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. A: 1.18 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
A' s 10-Year Yield on cost (5-Year) Range
Min: 0.31  Med: 1.22 Max: 1.42
Current: 1.18
0.31
1.42
Share Buyback Rate 1.60
A's Share Buyback Rate is ranked higher than
90% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.60 vs. A: 1.60 )
Ranked among companies with meaningful Share Buyback Rate only.
A' s 10-Year Share Buyback Rate Range
Min: 9.5  Med: 1.15 Max: -7
Current: 1.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 33.19
A's Price/Net Current Asset Value is ranked lower than
87% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.45 vs. A: 33.19 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
A' s 10-Year Price/Net Current Asset Value Range
Min: 2.8  Med: 11.23 Max: 153.61
Current: 33.19
2.8
153.61
Price/Tangible Book 9.36
A's Price/Tangible Book is ranked lower than
78% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. A: 9.36 )
Ranked among companies with meaningful Price/Tangible Book only.
A' s 10-Year Price/Tangible Book Range
Min: 1.1  Med: 3.53 Max: 12.49
Current: 9.36
1.1
12.49
Price/Projected FCF 1.14
A's Price/Projected FCF is ranked higher than
79% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. A: 1.14 )
Ranked among companies with meaningful Price/Projected FCF only.
A' s 10-Year Price/Projected FCF Range
Min: 0.62  Med: 0.96 Max: 3.07
Current: 1.14
0.62
3.07
Price/DCF (Earnings Based) 4.36
A's Price/DCF (Earnings Based) is ranked lower than
80% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. A: 4.36 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.21
A's Price/Median PS Value is ranked lower than
64% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. A: 1.21 )
Ranked among companies with meaningful Price/Median PS Value only.
A' s 10-Year Price/Median PS Value Range
Min: 0.39  Med: 0.91 Max: 1.66
Current: 1.21
0.39
1.66
Price/Graham Number 3.75
A's Price/Graham Number is ranked lower than
65% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. A: 3.75 )
Ranked among companies with meaningful Price/Graham Number only.
A' s 10-Year Price/Graham Number Range
Min: 0.78  Med: 1.62 Max: 4.25
Current: 3.75
0.78
4.25
Earnings Yield (Greenblatt) (%) 4.85
A's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. A: 4.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
A' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 5.70 Max: 17.1
Current: 4.85
0.3
17.1
Forward Rate of Return (Yacktman) (%) 5.21
A's Forward Rate of Return (Yacktman) (%) is ranked lower than
65% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. A: 5.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
A' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -0.6  Med: 7.00 Max: 78.6
Current: 5.21
-0.6
78.6

Analyst Estimate

Oct15 Oct16 Oct17
Revenue(Mil) 4,041 4,191 4,374
EPS($) 1.70 1.97 2.21
EPS without NRI($) 1.70 1.97 2.21

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ROP, GRMN, HXGBY, TRMB, NANO » details
Traded in other countries:AG8.Germany,
Agilent Technologies Inc was incorporated in Delaware in May 1999. The Company is a measurement company, providing core bio-analytical and electronic measurement solutions to the life sciences, chemical analysis, communications and electronics industries. It has three business segments comprised of the life sciences and diagnostics business, the chemical analysis business and the electronic measurement business. Its life sciences and diagnostics business provides application-focused solutions that include reagents, instruments, software, consumables, and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its product portfolio in life sciences and diagnostics business includes liquid chromatography systems, columns and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; Nuclear Magnetic Resonance, Magnetic Resonance Imaging, and X-Ray Diffraction systems; services and support for the aforementioned products; immunohistochemistry ; In Situ Hybridization; Hematoxylin and Eosin staining; special staining, DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation profiling; gene expression profiling; next generation sequencing target enrichment; and automated gel electrophoresis-based sample analysis systems. Its chemical analysis business provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. The product categories in chemical analysis include: gas chromatography (GC) systems, columns and components; gas chromatography mass spectrometry (GC-MS) systems; inductively coupled plasma mass spectrometry (ICP-MS) instruments; atomic absorption (AA) instruments; inductively coupled plasma optical emission spectrometry (ICP-OES) instruments; molecular spectroscopy instruments; software and data systems; vacuum pumps and measurement technologies; services and support for its products. Its electronic measurement business provides electronic measurement instruments and systems, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment, and microscopy products. Related services include start-up assistance, instrument productivity and application services and instrument calibration and repair. It also offers customization, consulting and optimization services throughout the customer's product lifecycle. The Company's competitors include Bruker Corp., Danaher Corporation, Ther
» More Articles for A

Headlines

Articles On GuruFocus.com
Agilent Technologies Drop Means Buy Now Aug 27 2015 
Why Agilent Technologies is a "Hold" Jun 17 2015 
Buy the Keysight Technologies Spinoff After the Dip Jun 17 2015 
Garmin: A Bargain for Patient Investors Apr 30 2015 
Weekly 52-Week Highs Highlight: ADS, CHT, A, KYO, LFC Apr 12 2015 
Agilent Has Focused on Several Strategic Actions Mar 20 2014 
Chris Davis' Davis Funds 2013 Portfolio Managers Update Feb 27 2014 
$500 Billion Manager Brian Rogers’ About-Face on Apple Inc. Dec 02 2013 
The Best Yielding Ex-Dividend Stocks on March 28, 2013 Mar 27 2013 
comment on A Mar 15 2013 

More From Other Websites
Agilent Technologies Collaborating with Weill Cornell Medical College to Advance Research in ALS Aug 26 2015
Agilent Technologies Collaborating With Weill Cornell Medical College to Advance Research in ALS Aug 26 2015
RainDance pulls IPO citing market conditions Aug 24 2015
Here’s what CEOs said about the economy this week Aug 21 2015
Agilent Technologies, Inc. Earnings Analysis: By the Numbers Q2*, 2015 Aug 20 2015
Agilent Technologies (A) Stock Earnings Estimates Lowered at Leerink Aug 18 2015
Agilent Technologies (A) Beats on Q3 Earnings & Revenues Aug 18 2015
Top Analyst Upgrades and Downgrades: Agilent, SanDisk, SunEdison, Urban Outfitters, Walt Disney and... Aug 18 2015
Watch These After-Hours Movers On Tuesday Aug 18 2015
Edited Transcript of A earnings conference call or presentation 17-Aug-15 8:30pm GMT Aug 17 2015
Urban Outfitters shares volatile after earnings beat Aug 17 2015
Agilent Technologies Reports Third-Quarter 2015 Results Aug 17 2015
Agilent Technologies (A) Stock Down in After-Hours Trading on Lower Guidance Aug 17 2015
Agilent Slips: FYQ3 Beats, Q4 View Light Aug 17 2015
Agilent Beats on Profits, but Guidance Does Not Match Analyst Expectations Aug 17 2015
Agilent Technologies Inc Earnings Call scheduled for 4:30 pm ET today Aug 17 2015
Agilent beats Street 3Q forecasts Aug 17 2015
Agilent beats Street 3Q forecasts Aug 17 2015
AGILENT TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 17 2015
Agilent Technologies Reports Third-Quarter 2015 Results Aug 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK